No Data
No Data
Hold Rating on Immunic Amidst Ongoing Vido Clinical Trials and Financial Outlook
Immunic, Inc. (NASDAQ:IMUX) Q1 2024 Earnings Call Transcript
Immunic | 10-Q: Quarterly report
Immunic Says It Bolstered Balance Sheet Through Three-tranche Private Placement Totaling Up To $240M, Extending Cash Runway Into Q3 2025, Based On Initial $80M Tranche
Immunic Says It Bolstered Balance Sheet Through Three-tranche Private Placement Totaling Up To $240M, Extending Cash Runway Into Q3 2025, Based On Initial $80M Tranche
Immunic: Q1 Earnings Snapshot
Immunic Q1 EPS $(0.30) Misses $(0.26) Estimate, Cash And Equivalents As Of March 31, 2024 Were $97.3M
Immunic (NASDAQ:IMUX) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.26) by 15.38 percent. This is a 48.28 percent increase over losses of $(0.58) pe